Molecular biomarkers in diagnosis of bladder cancer
A. A. Shiryaev,
A. V. Govorov,
A. O. Vasieliev,
A. V. Okishev,
Yu. A. Kim,
M. S. Fedina,
P. I. Bykov,
D. Yu. Pushkar https://doi.org/10.17650/1726-9776-2020-16-1-100-105
Abstract
Rapid development of genomic studies has led to development of new molecular biomarkers for diagnosis of primary and recurrent forms of bladder cancer. The study objective is to evaluate the current status of molecular biomarkers for diagnosis of recurrence and/or progression of bladder cancer and possibilities of their clinical use. A search of literature published in the last several years in the Pubmed and MedLine databases was performed. The obtained data was analyzed, sensitivity, specificity, positive and negative prognostic value were determined. The requirements for quality and characteristics of molecular biomarkers vary significantly depending on a specific case. The clinical role of urine biomarkers in observation of patients with nonmuscle invasive bladder cancer remains uncertain. Assays approved by the U.S. Food and Drug Administration do not demonstrate desired sensitivity and specificity which leads to their limited use. Currently, commercial assays of urine biomarkers are not sufficiently studied which predetermines further search for the optimal method of early diagnosis of bladder cancer. Multicenter clinical studies will allow to determine the place of each molecular biomarker in clinical practice.
About the Authors
A. A. Shiryaev
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Urology
Build. 1, 20 Delegatskaya St., Moscow 127473
A. V. Govorov
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russi
Russian Federation
Russian Federation
Department of Urology
Build. 1, 20 Delegatskaya St., Moscow 127473
A. O. Vasieliev
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russi
Russian Federation
Russian Federation
Department of Urology
Build. 1, 20 Delegatskaya St., Moscow 127473
A. V. Okishev
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russi
Russian Federation
Russian Federation
Yu. A. Kim
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russi
Russian Federation
Russian Federation
Department of Urology
Build. 1, 20 Delegatskaya St., Moscow 127473
M. S. Fedina
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russi
Russian Federation
Russian Federation
Department of Urology
Build. 1, 20 Delegatskaya St., Moscow 127473
P. I. Bykov
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russi
Russian Federation
Russian Federation
Department of Urology
Build. 1, 20 Delegatskaya St., Moscow 127473
D. Yu. Pushkar
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russi
Russian Federation
Russian Federation
Department of Urology
Build. 1, 20 Delegatskaya St., Moscow 127473
References
1. Tilki D., Burger M., Dalbagni G. et al. Urine markers for detection and surveil-lance of non-muscle-invasive bladder cancer. Eur Urol 2011;60(3):484–92. DOI: 10.1016/j.eururo.2011.05.053.
2. Berdnikov A.N., Volkova M.I., Karyakin O.B. et al. Clinical guidelines. Bladder cancer, 2017. Pp. 7–8. (In Russ.).
3. Grubmuller B., Roupret M., Briganti A., Shariat S.F. The use of biomarkers for bladder cancer diagnosis and surveillance. Mini Rev Med Chem 2016;16(18): 1444–9.
4. Ya F.A. Prospective analysis of sensitivity and specifity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 2015;33(66):25.
5. Seideman C., Canter D., Kim P. et al. Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? World J Urol 2015;33(9):1309–13. DOI: 10.1007/s00345-014-1452-9.
6. Babjuk M., Böhle A., Burger M. et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71(3):447–61. DOI: 10.1016/j.eururo.2016.05.041.
7. Kamat A.M., Hegarty P.K., Gee J.R. et al. ICUD–EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 2013;63(1):4–15. DOI: 10.1016/j.eururo.2012.09.057.
8. Chang S.S., Boorjian S.A., Chou R. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016;196(4):1021–9. DOI: 10.1016/j.juro.2016.06.049.
9. Mbeutcha A., Lucca I., Mathieu R. et al. Current status of urinary biomarkers for detection and surveillance of bladder cancer. Urol Clin North Am 2016;43(1):47– 62. DOI: 10.1016/j.ucl.2015.08.005.
10. Lotan Y., O’Sullivan P., Raman J.D. et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol 2017;35(8):531.e15– 22. DOI: 10.1016/j.urolonc.2017.03.008.
11. Yafi F.A., Brimo F., Steinberg J. et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol Semin Orig Investig 2015;33:66.e25–31.
12. Bell M.D., Yafi F.A., Brimo F. et al. Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. World J Urol 2016;34(10):1405–9. DOI: 10.1007/s00345-016-1795-5.
13. Pichler R., Tulchiner G., Fritz J. et al. Urinary UBC Rapid and NMP22 Test for bladder cancer surveillance in comparison to urinary cytology: results from a prospective single-center study. Int J Med Sci 2017;14(9):811–9. DOI: 10.7150/ijms.19929.
14. Shariat S.F., Savage C., Chromecki T.F. et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decisioncurve analysis. Cancer 2011;117(13):2892– 7. DOI: 10.1002/cncr.25903.
15. Shariat S.F., Zippe C., Lüdecke G. et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005;173(5):1518– 25. DOI: 10.1097/01.ju.0000154696.48217.75.
16. Babjuk M., Soukup V., Pes l M. et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 2008;71(4):718–22. DOI: 10.1016/j.urology.2007.12.021.
17. Raitanen M.P. FinnBladder group. The role of BTA stat test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 2008;26(1):45–50. DOI: 10.1007/s00345-007-0230-3.
18. Sarosdy M.F., deVere White R.W., Soloway M.S. et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995;154(2 Pt 1):379–83. DOI: 10.1097/00005392-199508000-00013.
19. Cha E.K., Tirsar L.A., Schwentner C. et al. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 2012;61(1):185–92. DOI: 10.1016/j.eururo.2011.08.073.
20. Mian C., Maier K., Comploj E. et al. uCyt+/ImmunoCytTM in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006;108(1):60–5. DOI: 10.1002/cncr.21712.
21. Lotan Y., Bensalah K., Ruddell T. et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2008;179:2164–9.
22. Schlomer B.J., Ho R., Sagalowsky A. et al. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2010;183(1):62–7. DOI: 10.1016/j.juro.2009.08.157.
23. Messer J., Shariat S.F., Brien J.C. et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 2011;108(5):701–5. DOI: 10.1111/j.1464-410X.2010.09899.x.
24. Karakiewicz P.I., Benayoun S., Zippe C. et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006;97(5): 997–1001. DOI: 10.1111/j.1464410X.2006.06036.x.
25. Tilki D., Burger M., Dalbagni G. et al. Urine markers for detection and surveil-lance of non-muscle-invasive bladder cancer. Eur Urol 2011;60(3):484–92. DOI: 10.1016/j.eururo.2011.05.053.
Review
For citations:
Shiryaev A.A., Govorov A.V., Vasieliev A.O., Okishev A.V., Kim Yu.A., Fedina M.S., Bykov P.I., Pushkar D.Yu. Molecular biomarkers in diagnosis of bladder cancer. Cancer Urology. 2020;16(1):100-105. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-1-100-105
Views:
679
Email this article 